BAM15: Difference between revisions

Content deleted Content added
Line 1:
'''BAM15''' BAM15 decreases [[hepatic]] [[fat]], decreases inflammatory [[lipids]], and has strong [[antioxidant]] effects. Hyperinsulinemic-euglycemic clamp studies show that BAM15 improves insulin sensitivity in multiple tissue types. Collectively, these data demonstrate that pharmacologic [[mitochondrial]] uncoupling with BAM15 has powerful anti-obesity and insulin sensitizing effects without compromising lean mass or affecting [[food]] intake.<ref>{{cite web |title=Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice |url=https://www.nature.com/articles/s41467-020-16298-2 |website=nature |accessdate=16 June 2020}}</ref>
 
said John Kirwan, Ph.D., Executive Director of the Pennington Biomedical Research Center in Baton Rouge, Louisiana. "Halting the obesity epidemic requires new, more effective medications. This research represents a very promising step in the discovery process. We hope that in the not-too-distant future, BAM15 or related compounds will advance to clinical drug development and become a viable treatment option for patients with obesity."<ref>{{cite web |title=A new study |url=https://medicalxpress.com/news/2020-06-bam15-potential-treatment-obesity.html |website=medicalxpress |accessdate=16 June 2020}}</ref>
 
said John Kirwan, Ph.D., Executive Director of the [[Pennington Biomedical Research Center]] in [[Baton Rouge]], [[Louisiana]]. "Halting the obesity epidemic requires new, more effective [[medications]]. This research represents a very promising step in the discovery process. We hope that in the not-too-distant future, BAM15 or related [[compounds]] will advance to clinical [[drug]] development and become a viable treatment option for [[patients]] with obesity."<ref>{{cite web |title=A new study |url=https://medicalxpress.com/news/2020-06-bam15-potential-treatment-obesity.html |website=medicalxpress |accessdate=16 June 2020}}</ref>
 
== References ==